chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills, weakness, cough, runny nose, trouble breathing. Saturday  the 27 is when it started, she woke with all these symptoms, she needed assistance with everything  she normally does by herself ex: taking shower, getting dressed.  Everyday after she got 10% better and as of this notice she still isn?t back 100%.. She better than she was but suffering from the effects. She?s not going to get second shot because she says it will kill her. I want her to get it but if the 2nd shot is worse than first I can?t in good conscience let her get it.
1/28/2022- Presented to ER, dizziness, SOB and vomiting. Afebrile, RR-27. O2 sat 96% on 3L.  Chest x ray-Moderate groundglass infiltrates . Chest CT-No evidence of Regulatory Authority  AKI-CRP-1.6 and GFR-37. Covid + test. Admit for acute respiratory failure secondary to Covid-19.  Started on IV azithromycin, IV ceftriaxone, doxycycline, IV Decadron, Lovenox and remdesivir.  2/1/2022- Stable, afebrile. Continues on 3L via NC o2 sat high 90's, trialling RA and able to sat around 96%.  Remdesivir last dose. IV Rocephin d/c start oral doxycycline. GFR decreased to 31. Discharged to home with oxygen support.
Menstrual cramps; Soreness of the left arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness of the left arm) and DYSMENORRHOEA (Menstrual cramps) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for an unknown indication.     No Medical History information was reported.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Soreness of the left arm) and DYSMENORRHOEA (Menstrual cramps). At the time of the report, PAIN IN EXTREMITY (Soreness of the left arm) and DYSMENORRHOEA (Menstrual cramps) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
8 doses given today after vial was punctured 30May2021; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (8 doses given today after vial was punctured 30May2021) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (8 doses given today after vial was punctured 30May2021). On 01-Jun-2021, EXPIRED PRODUCT ADMINISTERED (8 doses given today after vial was punctured 30May2021) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  Treatment information was not provided.
Father of the child brought the child for vaccination of first dose. Explains ex-wife (mother of the children) told him to get them vaccinated himself. Came for first dose. After arriving home to leave the children, he told her next dose will be on march, she responded they are allready vaccinated "you are responsible for whatever happen to the kids". He came back to vaccination site to inform what happened.
felt very light headed; really came very close to fainting/ she really thought she was gonna fall out of the chair; felt lethargic and fatigued on and off since the vaccine; felt lethargic and fatigued on and off since the vaccine/ at times more tired than normal; This is a spontaneous report received from a contactable consumer. The reporter is the patient.  A 57-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection), administration date 16Mar2021 (Lot number: ER2613, Expiration Date: 31Jul2021) at the age of 57 years as dose 1, single for COVID-19 immunisation. Relevant medical history included: "Diabetes Type II", start date: 2011 (unspecified if ongoing), notes: 10 years; "Blood pressure high" (unspecified if ongoing); "High cholesterol" (unspecified if ongoing); "kidney stones" (unspecified if ongoing); "had 2 kidney surgeries" (unspecified if ongoing), notes: for stones. Concomitant medications included: METFORMIN taken for diabetes mellitus; ALLOPURINOL taken for nephrolithiasis; LISINOPRIL taken for hypertension; LIPITOR [ATORVASTATIN] taken for blood cholesterol increased; POTASSIUM CITRATE. The following information was reported: DIZZINESS (non-serious) with onset 16Mar2021, outcome "recovered" (17Mar2021), described as "felt very light headed"; PRESYNCOPE (non-serious) with onset 16Mar2021, outcome "recovered" (17Mar2021), described as "really came very close to fainting/ she really thought she was gonna fall out of the chair"; LETHARGY (non-serious) with onset Mar2021, outcome "not recovered", described as "felt lethargic and fatigued on and off since the vaccine"; FATIGUE (non-serious) with onset Mar2021, outcome "not recovered", described as "felt lethargic and fatigued on and off since the vaccine/ at times more tired than normal". Therapeutic measures were not taken as a result of dizziness, presyncope, lethargy, fatigue.  Additional information: About 5 minutes after getting the vaccine, the patient started having side effects. The bigger side effect she felt was she felt very light headed and she really came very close to fainting. Fatigue and lethargy had been also a side effect, the long term side effect. The lightheadedness has gone away but the fatigue and lethargy stayed with her really for about a week. She couldn't drive safely on 16Mar2021 but she did drive on 17Mar2021 with no problem. She had somewhere to be on 16Mar2021 she had to call a friend to come and get her because she was not gonna to drive. The patient also mentioned she had a physical in Nov2020 which showed same result it shown forever, so her medication did not changed at all.  No follow-up attempts are possible. No further information is expected.
Information has been received from a physician concerning an 18 year old female who was vaccinated with the first and second dose of GARDASIL on unspecified dates. It was reported that there was no problem after either dose. On approximately 21-MAR-2008, the patient was given the third dose of GARDASIL. Four weeks following the third dose, approximately 21-APR-2008, the patient complained of aches, pains, and muscle soreness. The patient sought unspecified medical attention and underwent diagnostic laboratory tests eight weeks after the third dose of GARDASIL, approximately 21-MAY-2008. "ANE" and serum rheumatoid factor test were positive. No treatment or outcome information was provided. Additional information has been requested.
Patient reported muscle twitching following first dose of Moderna COVID vaccine. She states her symptoms began on 2/5/21 with tongue twitching, which subsided after less than a minute. She reports she had continued muscle twitches in both arms, both legs, and around both eyes intermittently for about one week. She says the muscle twitching did not happen at the same locations simultaneously. Patient reports no symptoms since 2/12/21. Patient discussed COVID vaccination with her doctor, who cleared her to receive the second dose. Patient vaccinated with second dose on 3/5/21 and encouraged to utilize V-Safe symptom tracker.
Broke out with slight rash on his chest 2 days after shots. The rash became more pronounced 6-11-07. Swelling of face hands and feet with fever of 102.7. On 6-12-07 seen in ER on 6/12/07 (regional hospital) Admitted for observation for with referral to dermatologist for (1) erythema multiforme major (2) otitis media (3) Dermatitis NOS.  06/19/2007 MR received for ER visit 6/12/07 for fever and rash.  Feet and hands swollen. PE:  (+) for bulging, red TM and yellow rhinorrhea.  Strawberry tongue.  Puplish macular rash on trunk with scalded appearance.  Purpuric lesions on buttocks and chest.  Target lesions on lower extremities. Conjunctivae red and eyes swollen.  Otherwise WNL. Impression:  Erythema multiforme major.  Left otitis media.
Rashes developed on both the arms.  It's been 11 days and the rash is getting worse by the day.
Headache; Vomiting; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 17 year-old male patient received bnt162b2 (BNT162B2), administration date 18Jun2021 (Lot number: EW0186) at the age of 17 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "Headache"; VOMITING (non-serious), outcome "unknown", described as "Vomiting".  No follow-up attempts are possible. No further information is expected.
Onset of intermittent headaches and tingling of the right hand began in mid December. The 2nd week of January, I had a transient episode of expressive aphasia that lasted about 1 minute. A week after that, a 2nd episode of expressive aphasia happened that was much longer which resulted in an ER visit and hospital admission. The subsequent work up showed a brain tumor in the left parietal lobe on an MRI scan. On 01/17/2023 I had a craniotomy which removed most of the tumor. Now I'm waiting for an oncology evaluation.
Hidradenitis suppurativa; Pain in joint involving hand; This spontaneous case was reported by a consumer and describes the occurrence of HIDRADENITIS (Hidradenitis suppurativa) and ARTHRALGIA (Pain in joint involving hand) in a 63-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Hidradenitis suppurativa.    No Medical History information was reported.   On 10-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. In September 2021, the patient experienced HIDRADENITIS (Hidradenitis suppurativa) and ARTHRALGIA (Pain in joint involving hand). In 2021, ARTHRALGIA (Pain in joint involving hand) had resolved. At the time of the report, HIDRADENITIS (Hidradenitis suppurativa) outcome was unknown.            Concomitant Drugs Not Reported  The reporter's causality for the event(s) of pain in elbow to wrist after covid injection with Humira(adalimumab) was a reasonable possibility. the reporter's causality for the event(s) of hidradenitis suppurativa flare was not provided.  Treatment Drugs Not Reported  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
I have the aches, pain; headache; This case was reported by a consumer via call center representative and described the occurrence of pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced pain and headache. On an unknown date, the outcome of the pain and headache were unknown.   It was unknown if the reporter considered the pain and headache to be related to Shingrix.  Additioal details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient had aches, pain and headache from the 2nd dose of Shingrix shot, which was received the day before reporting date. The patient inquired was there the preference for ADA, acetaminophen or ibuprofen for pain. The follow up would not be possible as no contact details were available.  GSK note- since it was not clear when the vaccine received by the patient or when the adverse event occurred, worst case approach applied and date before the reporting date considered as vaccination date.
Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Weakness-Mild, Additional Details: PATIENT FELL OFF CHAIR AFTER HE GOT HIS PFIZER COVID VACCINE AND HIT HIS HEAD ON BOARD.  HE DEVELOPED A BRUISE ON FOREHEAD. PATIENT LOOKED PALE. PHARMACY TECHNICIAN GAVE HIM SOME WATER AND TARGET STAFF APPLIED ICE PAK ON FOREHEAD AND OFFERED HIM SOMETHING TO EAT
bumps in his nostrils; In his mouth he has little sores; has little pimples on his chest, stomach, and head; he was thinking it was a hypersensitivity reaction because around his lips where his teeth meet it is very sensitive like you chewed on the side of the mouth; around his lips where his teeth met was very sensitive; This is a spontaneous report received from a contactable consumer (patient). This 48-year-old male patient received dose 1 of BNT162B2 (PFIZER BIONTECH COVID-19 MRNA VACCINE) via an unspecified route of administration on 17Mar2021 as a single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date "this weekend," the patient started getting little pimples. He had bumps in his nostrils, little bumps and only a couple. In his mouth he had little sores. He had little pimples on his chest, stomach, and head. They were tiny and nothing big. It was not that big of a deal. It was like a rash but not like a rash. He had bumps randomly, not a rash just bumps randomly here and there like pimples. He was thinking it was a hypersensitivity reaction because around his lips where his teeth met was very sensitive like you chewed on the side of the mouth. The events were reported as non-serious. The outcomes of little pimples on his chest, stomach, and head; bumps in his nostrils, in his mouth he had little sores, hypersensitivity reaction, and around his lips where his teeth met was very sensitive were unknown.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.
Information has been received from a healthcare worker referring to two unidentified patients of unknown age and gender. On unknown dates (range between 18-FEB-2015 to 30-MAR-2015) the patients were possibly vaccinated with one dose of improperly stored PNEUMOVAX 23 (lot # J011045, expiration date 15-MAY-2015, dose and route were unknown). No adverse effects reported. This is one of several reports received from same source. Additional information has been requested.
pt had a positive COVID test 9/2/21; pt in hospice; pt expired in hospice on 10/3/21
nonviable after a temperature excursion; This case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a female patient who received Men B NVS (Bexsero) (batch number ABXB28AA, expiry date 30th June 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On an unknown date, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.    This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were reported as follows: The age at vaccination was not reported. The patient was twin. The patient was given a dose of Bexsero that was deemed nonviable after a temperature excursion, which led to incorrect storage of drug.  No symptoms were reported. This is one of the several cases reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021142812:same reporter US-GLAXOSMITHKLINE-US2021142813:same reporter US-GLAXOSMITHKLINE-US2021142815:same reporter US-GLAXOSMITHKLINE-US2021142816:same reporter US-GLAXOSMITHKLINE-US2021142817:same reporter US-GLAXOSMITHKLINE-US2021142818:same reporter US-GLAXOSMITHKLINE-US2021AMR151443:same reporter US-GLAXOSMITHKLINE-US2021AMR151436:same reporter US-GLAXOSMITHKLINE-US2021AMR151445:same reporter US-GLAXOSMITHKLINE-US2021142817:
Facial swelling and throat tightness. Took 25mg BENADRYL and was alright. No loss of work.
T101.5, irritability, achiness, x 2 wk, vomiting, staring spells, twitching in hands & arms, diarrhea;
Dizzy/light-headed upon standing (within minutes after injection) - Hands shaky/sweaty/clammy - "Medicine-like" taste in mouth within minutes after injection - Taken to hospital via ambulance and checked. Wife notified pharmacist that patient is fine and home.
patient experience pain at site of reaction but also experience numbness at lower left jaw/upper left neck which started a little after an hour after administration.  After patient got a good night's sleep, all symptoms disappeared after about 24 hours.
Initial information received on 18-Oct-2018 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 20 years old male patient who was vaccinated with a 0.5 ml dose of FLUZONE QUADRIVALENT (Batch number: UI997AA, expiration date: 30-JUN-2019, site of administration: right deltoid and route was not reported) on 07-Sep-2018 and FLUZONE (Batch number: UJ009AB, expiration date: 30-JUN-2019, site of administration: left deltoid and route was not reported) on 17-Oct-2018. Concomitant medications included TRUMENBA. The patient's medical history were not reported. It was an actual medication error due to extra dose administered (20 year old male received FLUZONE QUADRIVALENT on 07-Sep-2018 and 17-Oct-2018/No AE). No adverse event reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. List of documents held by sender: none.
Migraine; Joint stiffness; Skin feels hypersensitive especially at injection site; Body aches; A spontaneous report was received from a nurse concerning a 25-years-old, white, female patient who was participating in the mRNA-1273 Emergency Use Program and experienced multiple events of migraine, body aches, joint stiffness and skin feels hypersensitive at injection site.  The patient's medical history as provided by the reporter, included COVID-19 and allergy to amoxicillin/ clavulanic acid. Concomitant medications reported included fish oil, colecalciferol, cetirizine hydrochloride and vitamins.   On 23 Dec 2020, approximately sixteen hours prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 (lot number: 011J20A) intramuscularly in the left arm for COVID-19 prophylaxis.  On 24 Dec 2020, the patient experienced migraine, body aches, joint stiffness and injection site hypersensitivity. The treatment for the events included paracetamol, and the symptoms improved.   Action taken with mRNA-1273 in response to the events was not reported.   The outcome for the events, migraine, body aches, joint stiffness and skin feels hypersensitive at injection site, were unknown.; Reporter's Comments: This case concerns a 25-years-old, white, female patient who received their first of two planned doses of mRNA-1273 (Lot-# 011J20A; expiration date- unknown), reporting an unexpected event of migraine, joint stiffness, injection site hypersensitivity and an expected event of pain (body aches).  The event occurred 15 hrs. 52 min after vaccine administration. Due to the temporal association between the onset of events and administration of vaccine, a causal relationship cannot be excluded.
I have severe psoriasis that is being managed by Stelara. Prior to my vaccination, my skin was 99% clear. 2 and 1/2 days after receiving my vaccination my psoriasis is having a flare up. My inverse psoriasis is now back, causing my skin to fall off and bleed. I am unable to shower comfortably (contact with water is painful), I am at higher risk of infection, I am experiencing a high amount of discomfort, and will likely be unable to sleep well. Becuase I just received a vaccination, I am not able to receive a steriod injection to alleviate my symptoms and will be dealing with not having skin or a remedy for about 4 weeks. Inverse psoriasis effects skin folds and often occurs between buttock and into the vulva and vaginal opening. This is where I am experiencing the loss of skin and bleeding. I am also experiencing this under my breasts and stomach.
I had a breakthrough case of Covid I had fever over 100 body aches head congestion, tired.
Pt developed a rash behind her ears, on the back of her neck, and on her upper back about 15 minutes post vaccination. She reported feeling funny and like her heart was racing. Her pulse rate was 120. Her blood pressure was 180/100.
Patient/staff member came in to receive her 2nd dose of Moderna COVID-19 vaccine. Because she was a staff member, vaccinating staff assumed that she knew that it was time for the injection and it was not verified. She answered "no" to the nurse regarding the question, "Have you received a vaccine in the past 2 weeks?" After she received the vaccine, the nurse inputting the information realized the vaccine had been given 2 weeks too early. Patient/staff member did not experience any adverse reactions after the vaccine was given. She was told that if she experienced any side effects above and beyond the normal, she was to go to the ER over the weekend.
My adverse symptoms started on the day after I got my Moderna booster shot. At around 11:00 a.m. in the morning I woke up feeling not good. I had  Body/ Muscle achs all over my body. I had Cold Chills and a fever.  It pretty much lasted all day on Friday,  December 31st, 2021.  But it was gone the next day.
ADVERSE EVENTS: racing heartbeat, chest pain, high blood pressure TREATMENT: took prescribed dosages of Eliquis, Carvedilol, Metformin, Diltiazem, Nitrostat, Bayer aspirin 325 mg, and Diphenhydramine HCI 25 mg OUTCOME: after 96 hours, heartbeat still elevated;  chest pain reduced; blood pressure reduced but still elevated
Pain in shoulder joint that began immediately after injection and continued for 10 days, until I visited my internist. The soreness was not really muscle pain but centered in the shoulder joint. The injection site was actually quite high on my arm. Following the vaccination, I could not lift my left hand, brush hair, get dressed etc. without assistance. Driving with two hands was difficult, because it hurt to lift my left hand to the steering wheel. I could not lift my left hand above waist level. Pain was not relieved by over the counter pain relievers, and did not diminish in the 10 days following vaccination.